Dr. Joseph Bass MD, PhD
Associate Professor of Medicine and Neurobiology, NORTHWESTERN UNIVERSITY
Member of the Healthcare Council
Council Member Biography
Joseph Bass, MD, PhD is an Associate Professor of Medicine and Neurobiology at Northwestern University in Illinois (tenure active September 2009, Division of Endocrinology and Molecular Medicine). He was previously the Division Head of Endocrinology and Metabolism at Evanston Northwestern Healthcare from December 1999 through June 2009. Dr. Bass directs a federally-funded research program on obesity, diabetes, and lipid disease. He has expertise in treatment of obesity, diabetes, hypertension, and hypercholesterolemia. He is on the Scientific Advisory Board of both biotech and major pharma companies with a focus on obesity and diabetes drug discovery areas. A full list of Dr Bass' publications is available on his research website: http://www.biochem.northwestern.edu/bass. (This is me - Update Profile)
Employment History
- 2009 - Unspecified
- Associate Professor of Medicine and Neurobiology, NORTHWESTERN UNIVERSITY
- 1999 - 2009
- Division Head of Endocrinology and Metabolism, EVANSTON NORTHWESTERN HEALTHCARE
- 1993 - 1999
- Instructor of Medicine, THE UNIVERSITY OF CHICAGO
GLG NewsSM Analyses by Joseph Bass(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
Another Glinide: Where's the Beef?
March 28, 2008
Elixir Announces Completion of Enrollment in Pivotal Phase III Clinical Trial for New Diabetes Drug | www.pipelinereview.com
Elixir has turned to a strategy devoid of innovation by selecting a combination glinide (metiglinide) plus glucophage for treatment of type 2 diabetes. With the new availability of DPP4 inhibitors (sitagliptin/alogliptin) and incretin agonists (eg byetta), what is the prospect of another K channel antagonist. The old problems likely will still appear: hypoglycemia, weight gain, and possibly progression of pancreatic failure/cell death.
-
Warning on A1C Targets and Diabetes Death in ACCORD Trial
February 8, 2008
Hault of ACCORD Study Intensive Treatment Arm | www.nhlbi.nih.gov
Increased death from intensive A1C lowering in diabetic subjects raises new concerns about diabetes therapy, insulin use in combination with oral agents, and clinical biomarkers of disease complications.
-
Predicting Winners in Oral Diabetes Competition: Galvus, Alogliptin & Januvia
February 5, 2008
Galvus(R), A New Treatment For Patients With Type 2 Diabetes, Receives European Approval For Label Update Paving The Way For EU Launches | www.pipelinereview.com
Oral therapies improve complianceEU approval of Galvus does not erase US doubts
-
Alogliptin on the diabetes horizon.
January 9, 2008
Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S. | www.pipelinereview.com
Diabetes is on the rise globallyExisting oral therapeutics have significant drawbacks but are cheap (generic) and some have been in use for many years.
Leading institutions connect with Joseph Bass through GLG
GLG Study Groups with Joseph Bass(?)
| Study Group Name | No. Members |
|---|---|
| Experts in the Leisure & Lodging Council | 4887 |
| Experts in the Automotive Council | 3422 |
| Byetta Prescribers for Diabetes | 261 |
| Byetta Prescribers for Diabetes: Endocrinologists | 150 |
| Medical Geneticists (US) | 85 |
GLG Live Meetings with Joseph Bass(?)
Joseph Bass has not participated in any GLG Live Meetings.